Polycondensed Peptide-Based Polymers for Targeted Delivery of Anti-Angiogenic siRNA to Treat Endometriosis

• Published in: International journal of molecular sciences 2023-12, Vol.25 (1), p.13
• Main Authors: Egorova, Anna, Maretina, Marianna, Krylova, Iuliia, Kiselev, Anton
• Format: Article
• Language: English
• Subjects: Analysis; Angiogenesis; Blood vessels; Chemical bonds; Drugs; Endometriosis; Endometrium; Endothelium; Fertility; Gene expression; gene therapy; Genes; Genetic engineering; Homeopathy; integrins; Ligands; Materia medica and therapeutics; Medical research; Nanoparticles; peptide-based carriers; Peptides; Polymer industry; Polymers; siRNA delivery; Therapeutics; Toxicity; Tumors; Vascular endothelial growth factor; VEGFA
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25010013

Endometriosis (EM) is a prevalent gynecological disease characterized by the abnormal growth of tissue similar to the endometrium outside of the uterus. This condition is accompanied by the development of new blood vessels in endometriotic lesions. While surgical intervention is effective in removing endometriotic lesions, some patients require multiple surgeries. Therefore, finding non-surgical treatments for EM is of great interest. One of the promising approaches is anti-angiogenic therapy using siRNA-therapeutics to target the expression of the VEGFA gene. Peptide-based polymers have shown promise as siRNA delivery systems due to their biocompatibility and ease of modification. We conducted a study to evaluate the effectiveness of the R6p-cRGD peptide carrier as a non-viral vehicle for delivering siRNA to endothelial cells in vitro and endometrial implants in vivo. We investigated the physicochemical properties of the siRNA-complexes, assessed cellular toxicity, and examined the efficiency of GFP and VEGFA genes silencing. Furthermore, we tested the anti-angiogenic effects of these complexes in cellular and animal models. The transfection with siRNA complexes led to a significant increase in VEGFA gene knockdown efficiency and a decrease in the migration of endothelial cells. For the animal model, we induced endometriosis in rats by transplanting endometrial tissue subcutaneously. We evaluated the efficiency of anti-angiogenic therapy for EM in vivo using anti-VEGF siRNA/R6p-RGD complexes. During this assessment, we measured the volume of the implants, analyzed VEGFA gene expression, and conducted CD34 immunohistochemical staining. The results showed a significant decrease in the growth of endometriotic implants and in VEGFA gene expression. Overall, our findings demonstrate the potential of the R6p-cRGD peptide carrier as a delivery system for anti-angiogenic therapy of EM.